CSI Market
Sign In | Register

Bone Biologics (BBLG) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access BBLG quarterly Cash Flow →
From Bone Biologics through Dec 31 2021, changes in Dec 31 2025's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-3.11
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation0.26
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Accrued Interest Expense-
Warrants Issued With Line Of Credit-
Warrants Issued To Consultants-
Marketable Securities Gain Loss-
Options Issued To Consultants-
Stock Issued During Period Value Issued For Services-
Interest Expense-
Interest Expense Deducted From Loan Proceeds-
Shares Issued For Services Related Party-
Finance Cost Related To Public Offering-
Interest Payable Related Party-
Increase Decrease In Advances On Research And Development Contract Services0.05
Increase Decrease In Prepaid Financing Costs-
Increase Decrease In Accrued Legal Settlement-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accrued Interest Receivable, Net-0.01
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.09
Increase (Decrease) in Accrued Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Insurance0.04
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-2.69
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock4.35
Proceeds from Contributions from Parent0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-3.33
Cash Advance By Repayment To Parent-
Cash Proceeds From Stock Subscriptions-
Cash Received For Stock Subscriptions-
Cash Proceeds From Sale Of Stock-
Cash Overdraft-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations3.33
Proceeds From Issuance Of Common Stock A T M Costs0.35
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities4.70
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-2.69
Total Cash Flow2.01
4 historic quarters locked

Sign in to unlock the full Bone Biologics cash flow history.

Sign In Create Free Account

About Bone Biologics Corp Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: March 2, 2026
  • Source: form10-k.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-008564

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License